Market Alert: ASX200 at Critical Support – Reversal or Further Fall?
Hydrix Limited (ASX: HYD) reported improved financial performance for 1HFY25, driven by higher margins, cost reductions, and increased project sales. Hydrix Services recorded AU$7.4 million in contract sales orders, a 37% year-on-year increase, and achieved a cash operating profit of AU$0.4 million after cutting AU$0.8 million in overhead costs. The company’s cash operating loss (COL) improved to AU$0.39 million from AU$2.09 million in the prior period, with AU$1.1 million cash on hand.
Hydrix Ventures saw an AU$0.36 million valuation increase following Gyder Surgical’s FDA 510(k) clearance, highlighting Hydrix’s expertise in medical device development. With an AU$40 million project pipeline from 15 active clients, Hydrix anticipates strong sales momentum, particularly in the cardiac and medtech sectors. The company remains optimistic about policy-driven growth in cardiac monitoring products and expanding opportunities in global markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 15, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.